Finding better ways to treat brain blood vessel constriction after a stroke.
Official title: Development of biomarkers to optimize intrathecal nicardipine treatment for cerebral vasospasm and delayed cerebral ischemia after subarachnoid hemorrhage
Funded at Emory University · NIH-10908464 · Data updated 2026-11-12
This study is looking at how a medication called nicardipine can help people who have had a type of stroke called a subarachnoid hemorrhage by improving blood flow in the brain and reducing the risk of serious complications, and they're also trying to find ways to predict who will benefit the most from this treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | September 27, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $375,235 |
| NIH project number | 5R01NS130036-03 |
| Project ID | NIH-10908464 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients who have experienced a subarachnoid hemorrhage and are at risk for cerebral vasospasm.
✕Less likely to help
Patients who have not experienced a subarachnoid hemorrhage or those with other unrelated neurological conditions may not benefit from this research.
What this research studies
This research focuses on improving treatment for patients who experience cerebral vasospasm, a dangerous condition that can occur after a subarachnoid hemorrhage (a type of stroke). The team at Emory University is investigating the use of intrathecal nicardipine, a medication that helps widen blood vessels in the brain, to reduce the risk of delayed cerebral ischemia, which can severely affect recovery. They aim to develop biomarkers that can predict how well patients will respond to this treatment, using advanced non-invasive techniques to measure blood flow in the brain. By identifying the right patients for this therapy, the research hopes to enhance treatment outcomes and overall patient survival.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for patients recovering from subarachnoid hemorrhage, potentially improving survival rates and long-term recovery.
How similar studies have gone: Previous studies have shown promising results with the use of intrathecal nicardipine in similar patient populations, indicating potential for success in this research.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Sadan, Ofer — Emory University
- Study coordinator: Sadan, Ofer
Related research
Other NIH-funded projects on the same topics.
-
Cognitive screening after an aneurysmal brain bleed
Using patient questionnaires to find thinking and memory problems in people recovering from aneurysmal subarachnoid hemorrhage.
-
Blood test to predict delayed brain injury after an aneurysm bleed
This project is creating a blood test to spot which people who had a brain aneurysm bleed are likely to develop delayed brain injury in the days after the bleed.
-
3D brain blood vessel model to study subarachnoid hemorrhage and test therapies
A researcher will develop a 3D printed, biomimetic brain model to study subarachnoid hemorrhage and screen potential nanoparticle-based treatments.
-
Biomarkers to Fine-Tune Intrathecal Nicardipine for Brain Bleeding-Related Stroke
Researchers are testing biomarkers to personalize intrathecal nicardipine treatment for patients after subarachnoid hemorrhage to prevent brain damage.
-
Adropin as a shield for the brain after a brain hemorrhage
A potential treatment with adropin is being studied to protect brain cells after a subarachnoid hemorrhage and reduce stroke-like damage.
-
Manganese-based compound as a potential therapy for subarachnoid hemorrhage
A new manganese porphyrin-based drug is being explored as a possible treatment to reduce brain injury after a subarachnoid hemorrhage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.